Healthcare costs and outcomes in adult patients with juvenile idiopathic arthritis : a population-based study by Mars, N. J. et al.
 1 
 
 
Healthcare Costs and Outcomes 
in Adult Patients with Juvenile Idiopathic Arthritis: A 
Population-based Study 
 
  
Nina J Mars1, 2, Anne M Kerola1, 3, Markku J Kauppi3, 4, Matti Pirinen2,5,6, Outi Elonheimo1,7,  
Tuulikki Sokka- Isler8 
 
1 University of Helsinki, Faculty of Medicine, Helsinki, Finland 
2 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland 
3 Päijät-Häme Central Hospital, Lahti, Finland 
4 School of Medicine, University of Tampere, Tampere, Finland 
5 Helsinki Institute for Information Technology HIIT and Department of Mathematics and 
Statistics, University of Helsinki, Helsinki, Finland 
6 Department of Public Health, University of Helsinki, Helsinki, Finland 
7 FCG Finnish Consulting Group Ltd, Helsinki, Finland 
8 Jyväskylä Central Hospital, Jyväskylä, Finland 
 
 
Corresponding author: 
Nina Mars, MD 
University of Helsinki, Faculty of Medicine and Institute for Molecular Medicine Finland 
Postal address: Tukholmankatu 8, Biomedicum Helsinki, Helsinki, Finland 
Email address: nina.mars@helsinki.fi 
Phone number: +358408472156 
 
Abstract: 249 words 
Full manuscript: 3240 words   
 2 
ABSTRACT 
Objectives: Evidence of the economic burden and long-term outcomes of juvenile idiopathic 
arthritis (JIA) remain scarce. Our aim was to explore healthcare costs and long-term 
outcomes in adult patients with JIA. 
Methods: We identified all adult patients (≥ 18 years) with JIA who made Jyväskylä Central 
Hospital rheumatology unit visits between May 2007 and March 2016. We considered 
individual medians of time-dependent clinical variables. These data were linked to 
administrative data from the area from the fiscal year 2014, which includes information on 
all public health care contacts. Healthcare utilization is presented as direct costs in euros 
(€). Factors affecting direct costs were assessed with a generalized linear model (GLM). 
Results: In 218 patients, median DAS28-3 was < 2.6 in 88.6% in those under age 30, and 
in 72.9% in those over 30. Median HAQ was < 0.5 in 85.7% and 45.4%. In the utilization 
data (four municipalities, 137 patients) the total annual health services-related direct costs 
were 432 257€ (mean = 3 155€/patient/year). Patients using bDMARDs in 2014 for a total 
of 355 months numbered 36 (26.3%), and the annual cost of bDMARDs was estimated at 
355 000€. Those with active disease had mean costs 2.4-fold to those with low or no 
disease activity. A one-point increase in median raw HAQ incurred an average 228€ 
increase in annual costs (p = 0.03). 
Conclusions: Most adult patients with JIA seem to manage well with their arthritis, bearing 
in mind that there still is room for improvement in long-term outcomes. 
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INTRODUCTION 
Juvenile idiopathic arthritis (JIA) is a disease entity covering several distinct subtypes 
sharing chronic arthritis as a common feature, and with symptoms presenting before age 16 
(1). Current treatment regimens have led to better outcomes for a medical condition that 
formerly often inflicted pain and disability (2).  
 
Unexpectedly, little data exist on how patients with JIA are affected by rheumatic 
inflammation in adulthood. In data mainly from the era before biological disease-modifying 
anti-rheumatic drugs (bDMARDs), approximately half of all patients with JIA continued in 
adulthood to have detectable rheumatic inflammation (3).  
 
Active JIA associates with high health care costs in children (4). In the era of biologics, 
however, evidence of the economic burden remains scarce (5), particularly in adult patients 
with JIA. The economic burden of rheumatoid arthritis (RA) is actively under study (6-8), but 
small sample sizes and disease heterogeneity limit research in JIA. Moreover, healthcare 
utilization in children and adults may differ considerably. 
 
Administrative data have the potential to elaborate knowledge of healthcare resource 
utilization. We combined a population-based, longitudinal clinical dataset on patients at a 
rheumatology clinic with administrative data on health services-related direct costs to 
explore long-term outcome and such costs in adult patients with JIA. 
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METHODS 
Patients 
The population-based clinical data cover patients from the Jyväskylä Central Hospital (JCH) 
area (population 252 000), Finland. Healthcare utilization data were available for four 
municipalities in this area (population ~140 000 in 2014). Their primary care is delivered at 
the local healthcare centres, which rely on JCH for specialist treatment in rheumatic 
diseases. The flow diagram is in Figure 1. 
 
Healthcare utilization data 
The healthcare utilization dataset in the fiscal year 2014 came extracted from the electronic 
medical records (EMR) system for administrative purposes. It is based on routinely recorded 
information on all public healthcare contacts. A contact is defined as one encounter per 
diagnosis, for instance, an appointment, one inpatient episode, a phone call, or paperwork 
that includes logging onto the EMR. 
 
The data comprise contacts with all public healthcare providers in the defined region: 
physicians and allied health care professionals, including nurses and rehabilitation workers. 
Both primary and specialty care is covered, including outpatient care, inpatient wards, and 
the emergency department (ED). 
 
A system similar to diagnosis-related group (DRG), one suitable for both inpatient and 
outpatient care, served to classify contacts into groups based on recorded diagnoses, either 
ICPC-2 (International Classification of Primary Care, Second Edition) or ICD-10 
(International Classification of Diseases, 10th Revision). The primary diagnosis is recorded, 
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and often one or several secondary diagnoses. Our main utilization variable was all-cause, 
health services-related costs in euros (€) rounded to the nearest integer. This includes costs 
for both JIA-related and non-JIA-related multimorbidities. Costs are estimated by a cost-
estimation tool owned by Finnish Consulting Group (FGC Ltd). This tool is based on the 
assumption that costs of similar contacts with specific disease category, age, sex, 
healthcare unit and provider, and procedures are similar. The estimation tool is trained with 
a large body of data from both the study area and other municipalities. 
 
To avoid underestimating total costs, we included the costs of contacts without diagnosis 
codes. In the estimation tool, contacts with no diagnosis code acquire costs similar to the 
costs of contacts with similar background characteristics.  
  
Only health services-related direct costs were included. In terms of medication costs, we 
focused only on costs incurred by bDMARDs. Neither social services nor indirect costs were 
included. 
 
Clinical data 
Patients attending the JCH rheumatology unit are enrolled prospectively in a structured 
digital database (GoTreatIT® Rheuma application, DiaGraphIT®) (9), from which we 
identified all patients with JIA aged ≥18. GoTreatIT monitoring is part of hospital medical 
records and collects structured data. Data in GoTreatIT can therefore easily be used for 
register-based research. Because the data are from an adult rheumatology clinic, we were 
unable to distinguish disease subtypes. 
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Clinical data were collected systematically on every visit to the rheumatology unit between 
May 2007 and March 16th 2016. These data constitute repeated measures, of which we 
selected a median to avoid the effect of aberrant values, such as high erythrocyte 
sedimentation rate (ESR, mm/h) or C-reactive protein (CRP, mg/l) due to infections, and to 
express long-term level of disease activity and functional measures. We assessed disease 
activity by Disease Activity Score (DAS28-3(ESR)), pain by Visual Analogue Scale (VAS, 0-
100), and disability by Health Assessment Questionnaire index (HAQ, 0-3). For 
comparability across rheumatic diseases, DAS28 instead of Juvenile Arthritis Disease 
Activity Score (JADAS) is recorded. For DAS28-3, the cutoff values chosen were 2.6 and 
3.2, where ≥ 3.2 represents moderate to high disease activity, < 3.2 low disease activity, 
and < 2.6 minimal disease activity and remission. For HAQ index, we considered 0 to 0.5 
as none to mild disability, and above 0.5 as moderate to severe disability. 
 
Age is the age on January 1, 2014. Smoking status was grouped as never and ever smokers 
(self-reported smoking on at least one visit as of 2007), and medication data as never and 
ever users of DMARDs, bDMARDs, methotrexate, and oral glucocorticoids (prednisolone, 
combined with one prednisone user). We used all available information on medication in 
adulthood. Medication data are routinely collected as of 2007, but for approximately 10%, 
medication data (mainly medication use in adulthood) before 2007 has been retrospectively 
recorded. Costs of bDMARDs in 2014 based on the total months of use were assessed from 
the clinical data. We estimated the monthly cost to be 1 000€/patient (average retail price 
in 2014). Costs of bDMARDs administered at the hospital rheumatology clinic are by default 
included in the health services-related costs. The cost of conventional synthetic DMARDs 
could not be reliably retrieved.  
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We selected employment status recorded at the most recent visit to the rheumatology clinic, 
and categorized it as follows: 1) disabled or pensioner (combined as some had answered 
“pensioner” although, based on age, they were receiving disability pensions), 2) sick leave 
or rehabilitation, 3) unemployed, and 4) working or student. We included all causes of sick 
leave and disability, as they are never distinguishable in our data. 
 
Combining datasets 
In Finland, a register-based study requires no informed consent from study subjects, nor 
any ethics approval from clinics or hospitals. Approval for the study came from the medical 
records administration (JCH). We combined the utilization data and clinical data through 
each patient’s unique national identification number. 
 
We studied only adult patients (≥ 18 years on 1 January 2014, i.e. at the beginning of 
utilization data collection). From the longitudinal clinical data, we included all visits and 
measures made in adulthood (≥ 16 years, as the transition age from pediatrics is 16). 
 
Statistical analysis 
Our cost data are non-normally distributed and positively skewed. Average-cost analysis 
included also those with zero costs. For cost comparisons, we used the Wilcoxon rank sum 
test. For comparing continuous variables, we used the independent t-test when its 
assumptions were met, and otherwise the Wilcoxon rank sum test. For categorical data, we 
used Fisher’s exact test. In patients with JIA, as disease duration is proportional to age, we 
assessed only age. We compared patients under 30 with those over 30, as the latter have 
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fallen ill before the era of biologics. We note that possible differences in clinical 
characteristics between these two groups may also reflect factors other than medication 
history, such as differing disease durations and general ageing. 
 
A patient was classified as having active disease if making at least one visit to the 
rheumatology unit with DAS28-3 ≥ 3.2 in 2014. We compared the costs of these patients to 
the costs of those with DAS28-3 < 3.2 in 2014, which indicates remission or low disease 
activity. 
 
We assessed factors affecting annual costs in those with non-zero costs with a generalized 
linear model (GLM) using Gamma distribution and a log link function. Gamma distribution 
was our choice because it models non-negative data and allows for increasing variance as 
a function of the mean. We constructed univariate models for age, pain, raw HAQ score, 
and DAS28-3. All these variables were included in the multivariate analysis, adjusted by 
sex. No collinearity was detectable. We excluded six cases with costs exceeding the 
geometric mean by two standard deviations. To increase interpretability, we calculated 
average marginal effects for variables reaching statistical significance in the multivariate 
analysis. This displays how the annual costs are affected when a variable increases by one 
unit, while the other variables remain unchanged. 
 
We also applied a more robust approach by performing a linear regression of inverse normal 
transformed costs with otherwise a similar model construction as for the GLM but without 
outlier exclusion. 
 
 9 
No analysis to assess cost differences in those with zero and non-zero costs was performed 
due to the low number of those with zero costs. 
 
Data handling and statistical analyses were by R version 3.2.4. 
 
 
RESULTS 
Clinical outcomes  
The clinical data involved 218 JIA patients now adults. Patient characteristics and 
comparison between the 119 patients younger than 30 and the 99 older than 30 are in Table 
1. Average ESR and HAQ were higher in those over 30 (p < 0.001) and also VAS was on 
average 11.6 points higher in that group (p < 0.001). When excluding those over age 60, 
results remained unchanged (results not shown). 
 
In the 218 patients, between 2007 and 2016, the mean number of visits to the rheumatology 
clinic was 9.0 (median 7.0, IQR 3.0-11.0). Those patients with only one visit constituted 
10.1%. The mean observation time was 5.1 years (median 5.6 years, IQR 3.5-6.8), 
calculated from the first visit to the rheumatology clinic as of 2007, until data extraction in 
March 2016. 
 
A majority, 90.4%, had at some point received DMARDs, and 43.5% had received 
bDMARDs. In terms of long-term DAS28-3 and HAQ index, proportions per category are in 
Figure 2. At some point, 18.8% of patients had smoked. Human leukocyte antigen (HLA) 
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B27 was positive for 12.8% (HLA-B27 status available for 33.5%), and 6.4% were 
rheumatoid factor-positive (RF, status available for 50.9%). 
 
Distribution of employment status between the age groups differed (p < 0.001). In those over 
30, those retired or receiving part-time or full-time disability pensions numbered 26 (26.3%). 
Of these 26, 20 were under 63, which is currently the youngest regular retirement age in 
Finland. We may thus assume that at least 20 patients (20.2%) among those over age 30 
received disability pensions. In those over 30, ones on sick leave or in rehabilitation at the 
time of their most recent visit to the rheumatology clinic numbered 6 (6.1%). 
 
Healthcare resource utilization 
The administrative data are well-recorded: 82.6% for diagnosis codes and 97.8 to 100.0% 
for all other variables. Of the contacts with no diagnosis code, 71.3% were other than face-
to-face encounters, and 58.4% non-physician contacts, both of which incur lower costs than, 
for example, physician contacts. 
 
Healthcare utilization data were available for four municipalities in the area, comprising 137 
adult patients with JIA. The total annual health services-related direct costs in these patients 
were 432 257€ (mean costs = 3 155€/patient/year, median = 1 569€/patient/year). Those 
with no healthcare contacts during 2014 numbered 17 (12.4%). Those 81 living outside the 
area for which we have healthcare utilization data were similar to the 137 with utilization 
data. Their mean age was 34.3 (31.8 in the 137 with healthcare utilization data), 67.9% were 
women (76.6%), mean DAS28-3 was 1.9 (1.9), mean pain 22.0 (22.4), and mean HAQ index 
0.5 (0.4). 
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Cost distributions were similar by sex (p = 0.33). Average annual direct healthcare costs 
were lower (p < 0.001) in those 80 patients under age 30 (mean costs = 2 386€/year, median 
= 844€/year), compared with those 57 over 30 (mean costs = 4 235€/year, median = 2 
772€/year). 
 
Those with active disease, defined as at least one visit to the rheumatology unit with DAS28-
3 ≥ 3.2 in 2014, numbered 11 (8.0%). Their mean age was 32.4, mean DAS28-3 in 2014 
was 3.7, and mean costs were 6 827€/year (median costs = 7 076€/year). Their annual 
costs were higher (p < 0.01) than others’, i.e. those with DAS28-3 < 3.2 in 2014 indicating 
remission or low disease activity (mean costs = 2 835€/year, median costs = 1 311€/year), 
with their mean health services-related costs being 2.4 times as high. The disease activity 
parameters, and patient-reported outcomes for those with active disease and for those in 
remission or with low disease activity are in Table 2. 
 
The 17 patients with zero costs are included in our annual figures; after their omission, 
results remained unchanged. Specialty care accounted for 80.6% of total costs, primary care 
for 14.0%, and the emergency department for 5.4%. 
 
Factors affecting costs 
The only factor associated with costs both in the univariate and multivariate analysis was 
raw HAQ (β = 0.081, p = 0.03 in the multivariate analysis, marginal effect = 228€ for a one-
point increase, 95% CI 3-453€)(Table 3). A similar association also appeared with the 
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inverse normal transformed annual costs (raw HAQ β = 0.089, p = 0.001 in multivariate 
analysis, R2 = 0.25). 
 
Use of biologic DMARDs 
Of 137 patients in the healthcare utilization dataset, 36 (26.3%) used bDMARDs in 2014 for 
a total of 355 months (mean 9.9 months/patient, IQR 8-12 months). The total annual cost of 
bDMARDs in these patients was 355 000€, with the mean cost of bDMARDs being 9 
861€/patient/year. The annual health services-related direct costs for the 137 patients of 
432 257€ meant that the annual health services-related direct costs were not far from the 
annual costs of bDMARDs. 
 
 
DISCUSSION 
 
Our main observation was that most patients with JIA have low or no disease activity in 
adulthood - those with a long-term level of DAS28-3 less than 2.6 at ages under 30 
constituted 88.6% and at those over 30, 72.9%. Other studies show in approximately half of 
adult patients with JIA some detectable inflammation (3, 10). One study evaluating patients 
with disease onset between 1980 and 1985 found that 30 years later, active disease was 
present in 34% (11). Our own estimate of those with disease activity was much lower, 8%. 
That our results show more favourable outcomes compared to previous studies arises from 
our definition of active disease, which was based on DAS28-3, but they also may to some 
extent reflect the fact that anti-rheumatic medication is now much more effective than in the 
1980s. Our estimate of disease activity may not be directly comparable to others’ estimates, 
because our definition is narrow and confined to a single year. 
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Despite seeing a positive trend in terms of disease activity, there still exist patients in need 
of improved disease control. Almost one in ten had active disease in 2014. That 12.8% 
lacked data for DAS28-3 may indicate that these patients have no symptoms indicative of 
active JIA. 
 
Between countries, treatment outcomes, as well as costs, vary (12). Due to this 
heterogeneity and a scarcity of studies on adult patients, costs are not easily comparable. 
Our mean costs were  
3 155€/patient/year, with median costs 1 569€. We found that during the same fiscal year 
having an active disease meant that health services-related direct costs more than doubled. 
In RA, a large share of direct costs result from multimorbidities (13), a pattern likely to be 
present in our older patients, because multimorbidity is associated with age (14).  
 
As some patients were diagnosed before the 21st century, i.e. before the availability of 
biologics, we compared that group aged over 30 with those under 30. The latter presented 
with better long-term disease control as well as lower patient-reported outcome measures 
and costs compared to those over 30. Differences in HAQ and ESR are likely explainable 
by age, and age may also explain why in those over 30 long-term average VAS was higher.  
 
We considered all causes of sick leave and disability pension. In those under 30, disability 
was rare, but in those older, a disability pension was common, and in 54.6% the long-term 
average HAQ level exceeded 0.5. Still, most of those over 30 were relatively young, at a 
mean 44.6. A long history of JIA before the availability of modern, effective disease-
modifying drugs may have permanently affected their joints, reflecting poorly on disability 
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measures and healthcare costs. Disability was associated with higher costs: a one-point 
increase in raw HAQ (individual average level) yielded an average increase of 228€ in 
annual costs. 
 
Current treatment strategies emphasize early and aggressive use of conventional DMARDs, 
and use of bDMARDs in case of failure of first-line treatment. Medication expenditures 
represent a substantial part of annual costs, particularly regarding bDMARDs (12), a finding 
also evident here. Still, the increase in costs may not be as high as expected, and this 
increase may be advocated, considering the long-term benefits of inflammation alleviation 
(15). Good disease control may also bring economic benefits, a pattern seen in RA (8). The 
rheumatology unit in Jyväskylä is highly specialized, and the local healthcare supply chain 
is elaborate (9), which may positively influence resource utilization, at least in the long run. 
In Finland, bDMARDs are used when necessary, and nearly half the patients overall had at 
some point received them. In 2014, a fourth used bDMARDs. 
 
Our clinical data are longitudinal and population-based and include repeated evaluations of 
patient-reported outcomes. They are constantly updated with false diagnoses removed and 
corrected, thus increasing accuracy. Previous studies rely mainly on patient- or parent-
reported estimates for healthcare visits (4, 12), and costs are commonly estimated by 
average unit prices. Our utilization data rely on recordings by healthcare professionals, 
yielding more reliable data, with every visit leaving its mark in the system. All public 
healthcare professionals and providers were included, and our costs represent all-cause 
direct costs, including those of multimorbidities. 
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The Finnish healthcare system is mainly public and tax-funded. A private sector exists; it 
covers some occupational health services and treats some private insurance-holders. In 
Jyväskylä, rheumatic diseases are treated in public healthcare, but the costs of concurrent 
diseases may be underestimated. 
 
JIA is a heterogeneous disease: between subtypes, the course of disease, outcomes, and 
costs vary (11, 16, 17). Being unable to distinguish among its subtypes is thus a limitation. 
All JIA subtypes may not be equally represented in our dataset, and those who have reached 
drug-free remission already in childhood are not likely to be included since their follow-up is 
primarily in primary care. The use of DAS28 instead of JADAS may underestimate disease 
activity in JIA. These facts limit the comparability of our results with other outcome studies. 
Only four patients were lost to follow-up because of moving away before the end of follow-
up, leading to low or no individual costs. Costs are underestimated in terms of conventional 
DMARDs, analgesics, and medications of co-occuring diseases, which, however, usually 
incur lower costs than do bDMARDs. 
 
Our goal was to assess health services-related direct costs for this population. Work 
disability raises the burden on society, as costs due to sick leave, and other indirect costs 
represent a considerable portion of total costs in adult JIA patients (16). We assume that 
particularly in those over 30 these indirect costs are substantial. 
 
In conclusion, with current treatment regimens, most patients with JIA seem to do well with 
their arthritis, bearing in mind that room still exists for improvement in long-term outcomes. 
Our study suggests that with effective treatment strategies, we may see a positive trend in 
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terms of reducing disease activity and disability. Similar studies with even longer follow-up 
are necessary, and multimorbidity patterns and factors affecting healthcare costs warrant 
further research. 
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Table 1. Patient characteristics and comparison between patients under and over age 
30. For each, we considered the median of time-dependent clinical variables observed in 
adulthood (group means of individual medians ± SD). For HAQ index, we report also the 
proportion of those with an individual median of 0, and the proportion of those with HAQ 
index being 0 on the latest rheumatology clinic visit. 
  All Age < 30 Age ≥ 30 pa Missing data b 
  n = 218 n = 119 n = 99   % 
Age (years) 32.7 ± 13.9 22.8 ± 3.4 44.6 ± 12.0   0.0 
Women (%) 73.4 68.9 78.8 p = 0.12 0.0 
Body mass index (kg/m2) 25.0 ± 5.1 23.5 ± 4.4 26.7 ± 5.3  p < 0.001 1.8 
Ever smokers (%) 18.8 18.5 19.2 p ≈ 1 0.0 
CRP (mg/l) 4.0 ± 7.4 2.3 ± 3.1 6.0 ± 10.0 p < 0.001 9.2 
ESR (mm/h) 10.0 ± 9.4 7.6 ± 6.2 12.9 ± 11.7 p < 0.001 8.7 
DAS28-3 1.9 ± 0.8 1.7 ± 0.8 2.1 ± 0.8 p < 0.001 12.8 
Pain (VAS 0-100) 22.2 ± 21.0 17.0 ± 19.1 28.6 ± 21.4 p < 0.001 0.5 
HAQ index (0-3) 0.4 ± 0.6 0.2 ± 0.4 0.7 ± 0.7 p < 0.001 0.9 
HAQ index = 0 (%) 42.2 58.0 23.2   
Latest HAQ index = 0 (%) 48.2 64.7 28.3   
Latest SJC28 = 0 (%) 82.4 86.0 77.9   
Latest TJC28 = 0 (%) 77.2 81.3 72.1   
Medication in adulthood           
Ever DMARDs (%) 90.4 89.7 90.1 p ≈ 1 
18.8 
Ever methotrexate (%) 78.0 80.4 74.1 p = 0.37 
Ever prednisone/prednisolone (%) 49.7 39.2 61.7 p < 0.01 
Ever bDMARDs (%) 43.5 45.4 40.7 p = 0.55 
Employment status c           
Disabled or pensioner (%) 12.4 0.8 26.3 
p < 0.001 0.0 Sick leave or rehabilitation (%) 3.2 0.8 6.1 
Unemployed (%) 11.9 11.8 12.1 
Working or student (%) 72.5 86.6 55.6 
 
a Continuous variables: independent t-test appropriate for BMI. For all other continuous variables, 
we used the Wilcoxon rank sum test, when assumption of homogeneity of variance was violated  
Categorical variables: Fisher's exact test 
b As we considered medians of time-dependent clinical variables, missing data represents the percentage  
of unique patients missing data. The majority of missing data for medication is likely explained by patients needing no 
medication in adulthood. Similarly, those missing data for DAS28-3 are likely to be in remission with no symptoms 
indicative of active JIA. Of the patients in the healthcare utilization dataset, only 3.6% (5 out of 137 patients) had missing 
data for DAS28-3. 
c At the most recent visit to the rheumatology clinic. Includes also non-rheumatological causes of sick leave and 
disability. "Disabled" includes part-time disability pension. 
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ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, VAS = Visual Analogue Scale, bDMARDs = biologic disease-
modifying antirheumatic drugs, HAQ = Health Assessment Questionnaire, TJC28 = Tender 28-Joint Count, SJC28 = Swollen 28-
Joint Count 
 
 
 
 
 
Table 2. Disease characteristics for those with active disease (at least one visit with DAS28-
3 ≥ 3.2 in 2014) and those in remission or with low disease activity (DAS28-3 < 3.2 in 2014). 
We considered the median of time-dependent clinical variables observed in adulthood 
(group means of individual medians ± SD). 
 
  At least one DAS28-3 ≥ 3.2 in 2014 DAS28-3 < 3.2 in 2014 
Number of patients 11 126 
DAS28-3 3.1 ± 0.7 1.8 ± 0.7 
Pain (VAS 0-100) 30.1 ± 18.0 21.7 ± 19.4 
HAQ index (0-3) 0.9 ± 0.9 0.3 ± 0.5 
HAQ index = 0 (%) 18.2 46.8 
Ever DMARDs (%) 100.0 100.0 
Ever bDMARDs (%) 81.8 50.0 
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Table 3. Factors affecting annual health services-related direct costs. These were 
assessed in those with non-zero costs by univariate and multivariate regression models. For 
non-transformed costs we applied a generalized linear model (GLM) with Gamma 
distribution and a log link function. We also applied a more robust approach by performing 
linear regression on inverse normal transformed costs. 
 
 
 
 
HAQ = Health Assessment Questionnaire, DAS28 = Disease Activity Score 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Costs not transformed Costs transformed 
  Univariate Multivariate Univariate Multivariate 
  β p β p β p β p 
Age 0.014 0.08 -0.005 0.62 0.023 < 0.001 0.001 0.94 
Sex     0.074 0.77     -0.019 0.93 
Pain 0.014 0.01 0.009 0.18 0.020 < 0.001 0.007 0.17 
Raw 
HAQ 0.084 0.001 0.081 0.03 0.107 < 0.001 0.089 0.001 
DAS28-3 0.080 0.53 -0.087 0.56 0.263 0.02 0.009 0.94 
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Figure 1. Flow diagram. 
 
 
 
 
Figure 2. Proportions of long-term DAS28-3 and HAQ disability index (medians of individual 
repeated measures) in those 119 under and 99 over age 30. DAS28-3 median is based on 
average 4.8 visits to a rheumatology clinic in those with long-term DAS28-3 < 2.6, average 
5.4 visits in the group 2.6-3.2, and average 8.4 visits in the group ≥ 3.2. 
 
 
